Legal News

US lawmakers eye biosimilar-delay deals, but none are here yet

US lawmakers eye biosimilar-delay deals, but none are here yet
Published on: 27 February 2019
Published by: Law360
  • US lawmakers eye biosimilar-delay deals, but none are here yet
  • What is this development about?
  • Still new
  • Different incentives
  • A general slowdown

Article summary

Law 360, New York: Pay-for-delay deals staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring pharmaceutical costs and for antitrust enforcers who believe consumers are hurt when drug companies agree to postpone the introduction of generics. Promoting such competition for biological therapies may be next on Washington’s list. or take a trial to read the full analysis.

Popular documents